Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases
Revista Alergia México · 2024
DOI: 10.29262/ram.v71i1.1279 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Revista Alergia México, 2024. Verfasst von María Del Carmen Cano-Salas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Enfermedades Respiratorias (INER) "Ismael Cosío Villegas" of Mexico, Mexico City. carmencano09@gmail.com. Hauptthemen laut MEDLINE: Asthma, Cost of Illness. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca Foundation.
Abstract (Originalsprache)
Background
In Mexico, asthma is one of the top twenty causes of disease with 254,713 new cases reported in 2019. According to Phase 3 of the International Study of Asthma and Allergies in Childhood, the prevalence of asthma ranged from 5 to 14% in 6 Mexican cities with varied geographic conditions. The burden of this disease impacts the health system in terms of direct costs through increased hospitalization and treatment costs; and indirect costs such as school and work absenteeism.
Methods
A retrospective, longitudinal observational study comprised by data from 247 female asthma patients, annual direct costs were estimated including: visits, laboratory tests, pharmacological treatment and management of crisis or exacerbations, to determine the annal burden of the disease from an institutional perspective and according to Global Initiative for Asthma classification.
Results
The average annual cost was $43,813.92, which increased in relation to the need of inhaled corticosteroids and long-acting beta agonists dosage increase. The average doctor’s appointment cost was $2,004.57, $982.82 for crisis management and $2,645.95 for laboratory testing. Pharmacological treatment represented the main economic burden with an annual average cost of $38,180.58.
Conclusions
The present analysis shows the severity of asthma and auxiliary treatments like biologics were the main factors that increased direct attention costs. The results highlight a high economic burden for asthma within the context of the third level of care in Mexico’s public health system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto Nacional de Enfermedades Respiratorias (INER) "Ismael Cosío Villegas" of Mexico, Mexico City. carmencano09@gmail.com.
- Instituto Nacional de Enfermedades Respiratorias (INER) "Ismael Cosío Villegas" of Mexico, Mexico City. jlmiguel@me.com.
- HS Pharmacoeconomic Research, Mexico City.
- Instituto Nacional de Enfermedades Respiratorias (INER) "Ismael Cosío Villegas" of Mexico, Mexico City.
Förderung
- AstraZeneca Foundation
Zitieren
APA
Cano-Salas, M. D. C., Miguel-Reyes, J. L., Sánchez-Trejo, K., López-Estrada, E. D. C., Salas-Hernández, J., Arroyo-Rojas, M. E., Castañeda-Valdivia, M., Escobar-Preciado, M., Guzmán-Vázquez, S., García-García, S. R., & Soto-Molina, H. (2024). Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases. Revista Alergia México. https://doi.org/10.29262/ram.v71i1.1279
Vancouver
Cano-Salas MDC, Miguel-Reyes JL, Sánchez-Trejo K, López-Estrada EDC, Salas-Hernández J, Arroyo-Rojas ME, et al. Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases. Revista Alergia México. 2024. doi:10.29262/ram.v71i1.1279
BibTeX
@article{CanoSalas2024,
author = {Cano-Salas, María Del Carmen and Miguel-Reyes, José Luis and Sánchez-Trejo, Karen and López-Estrada, Erika Del Carmen and Salas-Hernández, Jorge and Arroyo-Rojas, Monserrat Evelia and Castañeda-Valdivia, Mauricio and Escobar-Preciado, Monserrat and Guzmán-Vázquez, Silvia and García-García, Sergio Ricardo and Soto-Molina, Herman},
title = {Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases},
journal = {Revista Alergia México},
year = {2024},
doi = {10.29262/ram.v71i1.1279}
}
EUVIMED